{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T15:09:31Z","timestamp":1693667371349},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neuraminidase inhibitors (NAIs) complement influenza virus infection management by helping to clear virus, alleviate symptoms, and reduce transmission. In a previous randomised study, we examined the effect of 4 NAIs on virus clearance and influenza symptoms in Japanese paediatric patients. In this second analysis, we examined the effects of NAI treatment on antibody responses and virus clearance, and the relationships between antibody responses and patients\u2019 infection histories (previous infection; asymptomatic infection via household members of same virus type\/subtype; vaccination), and between infection histories and viral kinetics. Haemagglutination inhibition (HI) antibody responses produced HI titres \u226540 by Day 14 of NAI treatment, in parallel with virus clearance (trend test <jats:italic>P<\/jats:italic>\u2009=\u20090.001). Comparing patients with and without influenza infection histories (directly or asymptomatic infection via household members) showed that infection history had a marked positive effect on HI antibody responses in patients vaccinated before the current influenza season (before enrolment). Current virus clearance was significantly faster in patients previously infected with the same virus type\/subtype than in those not previously infected, and clearance pattern depended on the NAI. Assessment of anti-influenza effects of antiviral drugs and vaccines should consider virus and antibody dynamics in response to vaccination and natural infection histories.<\/jats:p>","DOI":"10.1038\/s41598-019-47884-0","type":"journal-article","created":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T10:02:31Z","timestamp":1565863351000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antibody dynamics in Japanese paediatric patients with influenza A infection treated with neuraminidase inhibitors in a randomised trial"],"prefix":"10.1038","volume":"9","author":[{"given":"Nobuo","family":"Hirotsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Saisho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsutaka","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Shishido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"47884_CR1","unstructured":"Centers for Disease Control and Prevention. Disease Burden of Influenza, https:\/\/www.cdc.gov\/flu\/about\/disease\/burden.htm (2018)."},{"key":"47884_CR2","doi-asserted-by":"publisher","unstructured":"Committee on Infectious Diseases. Recommendations for Prevention and Control of Influenza in Children, 2017\u20132018. Pediatrics, 140, https:\/\/doi.org\/10.1542\/peds.2017-2550 (2017).","DOI":"10.1542\/peds.2017-2550"},{"key":"47884_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/irv.12505","volume":"11","author":"R Sruamsiri","year":"2017","unstructured":"Sruamsiri, R. et al. Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: a structural equation modelling approach. Influenza Other Respir Viruses. 11, 543\u2013555 (2017).","journal-title":"Influenza Other Respir Viruses."},{"key":"47884_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1098\/rsif.2016.0289","volume":"13","author":"C Hadjichrysanthou","year":"2016","unstructured":"Hadjichrysanthou, C. et al. Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. J R Soc Interface. 13, 1\u201312 (2016).","journal-title":"J R Soc Interface."},{"key":"47884_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","volume":"59","author":"RJ Cox","year":"2004","unstructured":"Cox, R. J., Brokstad, K. A. & Ogra, P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 59, 1\u201315 (2004).","journal-title":"Scand J Immunol."},{"key":"47884_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3851\/IMP3104","volume":"22","author":"Y Saisho","year":"2017","unstructured":"Saisho, Y., Ishibashi, T., Fukuyama, H., Fukase, H. & Shimada, J. Pharmacokinetics and safety of intravenous peramivir, neuraminidase inhibitor of influenza virus, in healthy Japanese subjects. Antivir Ther. 22, 313\u2013323 (2017).","journal-title":"Antivir Ther."},{"key":"47884_CR7","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.4049\/jimmunol.1002090","volume":"186","author":"EE Waffarn","year":"2011","unstructured":"Waffarn, E. E. & Baumgarth, N. Protective B cell responses to flu\u2013no fluke! J Immunol. 186, 3823\u20133829 (2011).","journal-title":"J Immunol."},{"issue":"aug10 1","key":"47884_CR8","doi-asserted-by":"publisher","first-page":"b3172","DOI":"10.1136\/bmj.b3172","volume":"339","author":"M. Shun-Shin","year":"2009","unstructured":"Shun-Shin, M. et al. Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials. BMJ. 339, https:\/\/doi.org\/10.1136\/bmj.b3172 (2009).","journal-title":"BMJ"},{"key":"47884_CR9","doi-asserted-by":"crossref","unstructured":"Hirotsu, N., Saisho, Y. & Hasegawa, T. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: a prospective, observational study. Influenza Other Respir Viruses.\u00a013, 123\u2013132 (2019).","DOI":"10.1111\/irv.12590"},{"key":"47884_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14787210.2018.1421945","volume":"16","author":"N Hirotsu","year":"2018","unstructured":"Hirotsu, N., Saisho, Y., Hasegawa, T. & Shishido, T. Clinical and virologic effects of four neuraminidase inhibitors in influenza A virus-infected children (aged 4\u201312 years): an open-label, randomized study in Japan. Expert Rev Anti Infect Ther. 16, 173\u2013182 (2018).","journal-title":"Expert Rev Anti Infect Ther."},{"key":"47884_CR11","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/v9080197","volume":"9","author":"P Cao","year":"2017","unstructured":"Cao, P. & McCaw, J. M. The mechanisms for within-host influenza virus control affect model-based assessment and prediction of antiviral treatment. Viruses. 9, 197 (2017).","journal-title":"Viruses."},{"key":"47884_CR12","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1016\/j.vaccine.2017.07.092","volume":"35","author":"S Ohfuji","year":"2017","unstructured":"Ohfuji, S. et al. Key points in evaluating immunogenicity of pandemic influenza vaccines: a lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine. Vaccine. 35, 5303\u20135308 (2017).","journal-title":"Vaccine."},{"key":"47884_CR13","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1001\/archinte.159.2.182","volume":"159","author":"WE Beyer","year":"1999","unstructured":"Beyer, W. E., de Bruijn, I. A., Palach\u00e8, A. M., Westendorp, R. G. & Osterhaus, A. D. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med. 159, 182\u2013188 (1999).","journal-title":"Arch Intern Med."},{"key":"47884_CR14","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/21645515.2015.1011562","volume":"11","author":"B Camilloni","year":"2015","unstructured":"Camilloni, B., Basileo, M., Valente, S., Nunzi, E. & Iorio, A. M. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: a literature review. Hum Vaccin Immunother. 11, 553\u2013563 (2015).","journal-title":"Hum Vaccin Immunother."},{"key":"47884_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1128\/JVI.02757-15","volume":"90","author":"G Koopman","year":"2016","unstructured":"Koopman, G. et al. Correlation between virus replication and antibody responses in macaques following infection with pandemic influenza A virus. J Virol. 90, 1023\u20131033 (2016).","journal-title":"J Virol."},{"key":"47884_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1743-422X-11-57","volume":"11","author":"J Lv","year":"2014","unstructured":"Lv, J. et al. Kinetics of pulmonary immune cells, antibody responses and their correlations with the viral clearance of influenza A fatal infection in mice. Virol J. 11, 57 (2014).","journal-title":"Virol J."},{"key":"47884_CR17","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1099\/jgv.0.000225","volume":"96","author":"H Sun","year":"2015","unstructured":"Sun, H. et al. Dynamics of virus shedding and antibody responses in influenza A virus-infected feral swine. J Gen Virol. 96, 2569\u20132578 (2015).","journal-title":"J Gen Virol."},{"issue":"50","key":"47884_CR18","doi-asserted-by":"publisher","first-page":"20657","DOI":"10.2807\/1560-7917.ES2013.18.50.20657","volume":"18","author":"A Zhang","year":"2013","unstructured":"Zhang, A. et al. Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro Surveill. 18, 20657, https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24342519 (2013).","journal-title":"Eurosurveillance"},{"issue":"3","key":"47884_CR19","doi-asserted-by":"publisher","first-page":"e1002082","DOI":"10.1371\/journal.pbio.1002082","volume":"13","author":"Adam J. Kucharski","year":"2015","unstructured":"Kucharski, A. J. et al. Estimating the life course of influenza A(H3N2) antibody responses from cross-sectional data. PLoS Biol. 13, https:\/\/doi.org\/10.1371\/journal.pbio.1002082 (2015).","journal-title":"PLOS Biology"},{"key":"47884_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/infdis\/jiu580","volume":"211","author":"XS He","year":"2015","unstructured":"He, X. S. et al. Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination. J Infect Dis. 211, 1051\u20131059 (2015).","journal-title":"J Infect Dis."},{"key":"47884_CR21","doi-asserted-by":"publisher","unstructured":"Kucharski, A., Lessler, J., Cummings, D. A. & Riley, S. Timescales of influenza A\/H3N2 antibody dynamics. BioRxiv, https:\/\/doi.org\/10.1101\/183111 (2017).","DOI":"10.1101\/183111"},{"key":"47884_CR22","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1126\/science.1256427","volume":"346","author":"JM Fonville","year":"2014","unstructured":"Fonville, J. M. et al. Antibody landscapes after influenza virus infection or vaccination. Science. 346, 996\u20131000 (2014).","journal-title":"Science."},{"key":"47884_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40506-016-0085-5","volume":"8","author":"H Zaraket","year":"2016","unstructured":"Zaraket, H. & Saito, R. Japanese surveillance systems and treatment for influenza. Curr Treat Options Infect Dis. 8, 311\u2013328 (2016).","journal-title":"Curr Treat Options Infect Dis."},{"key":"47884_CR24","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/infdis\/jit372","volume":"208","author":"S Ng","year":"2013","unstructured":"Ng, S. et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 208, 1320\u20131324 (2013).","journal-title":"J Infect Dis."},{"key":"47884_CR25","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1016\/S0264-410X(01)00219-5","volume":"19","author":"RJ Cox","year":"2001","unstructured":"Cox, R. J., Mykkeltvedt, E., Sjursen, H. & Haaheim, L. R. The effect of zanamivir treatment on the early immune response to influenza vaccination. Vaccine. 19, 4743\u20134749 (2001).","journal-title":"Vaccine."},{"issue":"Suppl 1","key":"47884_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2165\/00003088-199936001-00006","volume":"36","author":"A Webster","year":"1999","unstructured":"Webster, A., Boyce, M., Edmundson, S. & Miller, I. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet. 36(Suppl 1), 51\u201358 (1999).","journal-title":"Clin Pharmacokinet."},{"issue":"5","key":"47884_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3851\/IMP3222","volume":"23","author":"Masatoki Sato","year":"2018","unstructured":"Sato, M., Hashimoto, K., Kawasaki, Y. & Hosoya, M. Immune response after a single intravenous peramivir administration in children with influenza. Antivir Ther, https:\/\/doi.org\/10.3851\/IMP3222 (2018).","journal-title":"Antiviral therapy"},{"key":"47884_CR28","doi-asserted-by":"publisher","first-page":"6769","DOI":"10.1128\/JVI.00458-10","volume":"84","author":"YP Lin","year":"2010","unstructured":"Lin, Y. P. et al. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? J Virol. 84, 6769\u20136781 (2010).","journal-title":"J Virol."},{"key":"47884_CR29","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/infdis\/jix074","volume":"215","author":"DM Skowronski","year":"2017","unstructured":"Skowronski, D. M. et al. Serial vaccination and the antigenic distance hypothesis: effects on influenza vaccine effectiveness during A(H3N2) epidemics in Canada, 2010\u20132011 to 2014\u20132015. J Infect Dis. 215, 1059\u20131099 (2017).","journal-title":"J Infect Dis."},{"key":"47884_CR30","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.coi.2017.03.002","volume":"45","author":"Y Takahashi","year":"2017","unstructured":"Takahashi, Y. & Kelsoe, G. Role of germinal centers for the induction of broadly-reactive memory B cells. Curr Opin Immunol. 45, 119\u2013125 (2017).","journal-title":"Curr Opin Immunol."},{"key":"47884_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/0091270012440280","volume":"53","author":"K Chairat","year":"2013","unstructured":"Chairat, K., Tarning, J., White, N. J. & Lindegardh, N. Pharmacokinetic properties of anti-influenza neuraminidase inhibitors. J Clin Pharmacol. 53, 119\u2013139 (2013).","journal-title":"J Clin Pharmacol."},{"key":"47884_CR32","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1128\/AAC.00360-11","volume":"55","author":"S Kohno","year":"2011","unstructured":"Kohno, S. et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother. 55, 5267\u20135276 (2011).","journal-title":"Antimicrob Agents Chemother."},{"key":"47884_CR33","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1128\/AAC.06456-11","volume":"56","author":"H Ishizuka","year":"2012","unstructured":"Ishizuka, H., Toyama, K., Yoshiba, S., Okabe, H. & Furuie, H. Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers. Antimicrob Agents Chemother. 56, 3873\u20133878 (2012).","journal-title":"Antimicrob Agents Chemother."},{"key":"47884_CR34","doi-asserted-by":"publisher","first-page":"e0188267","DOI":"10.1371\/journal.pone.0188267","volume":"12","author":"AM Clark","year":"2017","unstructured":"Clark, A. M. et al. Antigenicity of the 2015\u20132016 seasonal H1N1 human influenza virus HA and NA proteins. PLoS One. 12, e0188267 (2017).","journal-title":"PLoS One."},{"key":"47884_CR35","unstructured":"R Core Team. The R Project for Statistical Computing, https:\/\/www.R-project.org\/ (2017)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47884-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47884-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47884-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:39:27Z","timestamp":1671280767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-47884-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["47884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-47884-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"assertion":[{"value":"2 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.H. has received honoraria from Shionogi & Co., Ltd. for giving promotional lectures regarding influenza infection and is an advisor to Shionogi & Co., Ltd. regarding anti-influenza drug development. Y.S., T.H., M.K. and T.S. are employees of Shionogi & Co., Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11891"}}